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SOUTH AFRICA IS A SIGNATORY TO WORLDHealth Assembly (WHA) resolution54.19 (May 2001), which calls for regular,
synchronized treatment of helminthiasis in
developing countries, particularly where the
prevalence of worm infestation exceeds 50%.
Helminthic infection is usually a hallmark of
poverty and reasons why it should be con-
trolled in disadvantaged communities are
compelling. However, existing South African
legislation regulating the procurement and
use of anthelminticmedicines effectively ren-
ders group-based deworming as agreed to by
WHA member states, and endorsed by the
South African minister of health, non-imple-
mentable in practice. In order to make
deworming sustainable, low-cost, unregis-
tered anthelmintics must be imported from
international procurement agencies. At pres-
ent, this is not permitted. Another problem is
that both medical and non-medical personnel
are confused by out-of-date information in
package-inserts regarding safety for young
children and pregnant women. Albendazole
and praziquantel should be de-scheduled and
ivermectin, levamisole and possibly nitazo-
xanide should be registered in a way that
permits treatment by non-medical personnel.
Rational alternation of medication is important
because reliance on mebendazole will lead to
resistance. All batches of anthelmintics ought
to comply with pharmacological quality
specifications and testing should be routine.
Facilities for doing this are available in South
Africa.
International policy
In May 2001, the South African minister
of health endorsed World Health Assem-
bly (WHA) resolution 54.19, which calls
for regular, synchronized treatment of
helminthiasis in high-risk groups when
the prevalence is 50% or more.1–3 Member
states are urged to sustain control as a
public health measure and ensure access
to essential drugs. It is proposed that in
communities where the prevalence of
worm infestation is excessive, treatment
programmes should reach 75–100% of
school-age children by 2010, as well as
other important groups such as pre-
school children and young women. These
objectives are based on the fact that regu-
lar treatment is the quickest way to allevi-
ate most of the huge burden of disease
caused by infection with worms in cate-
gories of people predisposed to infesta-
tion. A key aspect is that treatment should
be simultaneous for all children in a
school. This will reduce overall morbidity,
be of direct benefit to treated individuals
and have an advantageous epidemiologi-
cal effect by reducing the number of
worm eggs shed into the environment.
The WHA call for action came in a
decade within which a lot of information
on infection of South African children by
intestinal worms and protozoa has been
published.4–32 These data confirm that a
widespread problem exists, and there are
reasons why the situation may be deterio-
rating. A serious deficiency is that worm
infestation in young women has not
been studied. In KwaZulu-Natal (KZN),
Limpopo and Mpumalanga provinces, as
well as in neighbouring states, schistoso-
miasis and hookworm infection can occur
together in women of child-bearing age
and children.
While our main purpose is to assess
key South African aspects relating to
implementation of WHA resolution 54.19
on control of worm infestation, the
current and emerging threat posed by
pathogenic intestinal protozoa must be
recognized.2,33
Background to the WHA resolution
Globally, it is children and women in
particular who carry the greatest burden
of disease resulting from helminthiasis.1–3
It has been estimated that the loss in
disability-adjusted life years caused by
intestinal parasites is second only to
tuberculosis (TB) and exceeds that due to
malaria.2 Infection by soil-transmitted
helminths, schistosomes and cestodes
can, either alone or in combination,
impair health, growth, nutrition, learning
and physical performance.1–3,34–44 Damage
to vital organs and even the fetus, may be
serious and is sometimes irreversible.
Notably, a meta-analysis of randomized
controlled trials has reported a mean
weight gain of either 0.24 kg or 0.38 kg per
child, depending on the model used, after
a single treatment with any anthelmintic.37
This amounts to a massive effect over a
large number of children, which should
be cumulative if treatment starts at an
early age and is repeated regularly. It is
the kind of result that would be a strong,
long-term investment in health. Lastly,
urogenital schistosomiasis may be facili-
tating HIV infection by increasing contact
between blood, inflammatory cells and
the virus in semen and vaginal secretions.39
For epidemiological and immunological
reasons,2,20,45–48 regular, blanket deworming
could affect diseases that are co-endemic
with worm infestation in different ways.
Minimization of long-term contact with
helminthic antigens by sustained de-
worming may, in theory, facilitate immu-
nological protection against HIV/AIDS
and TB, but in doing so might increase
susceptibility to allergies and/or autoim-
mune diseases.20,32,45 The position regard-
ing atopic disorders is controversial. In
Cape Town, exposure to Ascaris has been
associated with exacerbation of allergic
asthma in a specific ethnic group, accord-
ing to reports published in 1979 and
1988.47,48 Research completed in 2004 has
confirmed this finding (C.C. Obihara,
unpubl. data). On balance, the potentially
beneficial results of regular deworming
should outweigh any that are detrimen-
tal. For example, when immunological
activation caused by intestinal parasites is
sustained, some vaccines are less effec-
tive, including bacille Calmette-Guérin
vaccine against TB and oral cholera vac-
cine.45 For the same reason, trials of some
potential anti-HIV vaccines may fail or
give misleading results.46 Since worm in-
festation is so widespread, regular, syn-
chronized deworming, especially of
children before sexual activity starts, may
be an economical way to minimize im-
pairment of vaccine trials, and might also
eventually make immunization more
effective. Furthermore, countering the
immune response to parasitic worms may
or may not result in slower disease pro-
gression after infection by HIV or Myco-
bacterium tuberculosis.32,45,49
A powerful demonstration of the
demand for deworming and of informed
consent in the African context is when
children who do not attend school run to
get treatment, as they have been seen
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to do in Cape Town, before temporary
facilities close or the tablets are finished.
Some of these children are not in school
because they are AIDS orphans. Africans
have probably always known that worm
infestation is a serious problem. There are
traditional deworming remedies, generally
derived from plants that have medicinal
properties. However, indigenous people
never lived at a population density of
34 000 per km2 in shacks at ground level,
as in parts of Sites B and C in Khayelitsha,
Cape Town, and other informal settle-
ments, before they started migrating to
cities and towns in search of work and
health care.12,20,24 Neither traditional Afri-
can medicine nor conventional health
services can cope with the new situation.
Yet under these conditions synchronized,
school-based deworming can be a power-
ful overall health catalyst, as has been
shown by operational research in Khaye-
litsha.12 When children pass large Ascaris
worms soon after treatment with a single
tablet, it generates confidence in partici-
patory health care. One small, 8-year-old
girl passed 52 of these worms the first time
she was treated. It is highly significant
that children want and strive to get treat-
ment. They need to experience our re-
sponse to their call for help as being
direct, rapid and effective.
Implementation of WHA resolution
54.19 in South Africa
Given the compelling reasons why in-
festation by intestinal parasites should be
controlled, and with South Africa having
supported international policy that calls
for regular, group-based deworming of
children and women living in poverty,
the question arises as to whether we can
deliver on deworming in our own country.
The short answer is that we cannot, for
more than one reason.
Only one anthelmintic can be used at
present
The Medicines and Related Substances
Control Act (No. 101 of 1965), as partially
amended by the Medicines and Related
Substances Control Amendment Act (No.
90 of 1997; subsequently referred to as
‘the Act’), is inadvertently preventing im-
plementation of WHA resolution 54.19 in
South Africa by restricting the use of
deworming medicines through the re-
quirements for registration, scheduling
and dispensing. Only mebendazole (a
benzimidazole) has the potential to be
used, subject to limitations on dispensing,
because it is a Schedule 1 (S1) medicine.
Reliance on a single anthelmintic (i.e.
mebendazole) would be bad practice be-
cause there is potential for development
of resistance.1,2,50,51 To reduce this risk,
non-benzimidazoles such as ivermectin
and levamisole could be used alternately
with benzimidazoles, but they are not
registered in this country. Ivermectin is
also effective against skin parasites such
as scabies mites and jigger fleas, both of
which are known to cause problems in
South Africa.
Other essential anthelmintics for group-
based therapy are albendazole and
praziquantel but they are Schedule 4 (S4)
medicines. This means that they can be
used legally only under prescription for
treatment of individuals. There have been
millions of safe treatments with both of
these anthelmintics around the globe for
many years.1–3,50–55 Albendazole is the drug
of choice against hookworm that occurs
in parts of South Africa, Mozambique and
Zimbabwe.5,8,18,21,27,28 These parasites are
one cause of anaemia, low iron status and
growth stunting because they feed on
blood obtained by biting into the intesti-
nal surface, with release of hydrolytic
enzymes and anticoagulant that promote
bleeding.43 Praziquantel is needed to treat
schistosomiasis (bilharzia), a disease
which can cause serious damage to
various organs, including the spinal cord
and fetus.1–3,18,29,52,54,55 Schistosomiasis is
present in five South African provinces
(especially KZN) and all neighbouring
states except Lesotho.18,22 Praziquantel is
also effective against tapeworms and
soil-transmitted helminths, and is used in
the treatment of cysticercosis and hydatid
disease.
Nitazoxanide (Alinia®, Romark Labora-
tories) is a relatively new compound that
is effective against intestinal worms as
well as some protozoa and bacteria.51,56 On
the basis of studies that have found it to be
efficacious and safe, it should be assessed
for possible registration in South Africa
for use in both group-based and individ-
ual therapy.
Restrictions on the use of anthelmintics
The Act does not authorize non-medical
personnel to treat with scheduled medi-
cines. Even in the S1 category, there are
limitations that have the potential to
block treatment by the teachers, environ-
mental health officers (EHOs), commu-
nity health-workers, parents, NGO
personnel and other lay volunteers who
must participate directly if implementa-
tion of WHA resolution 54.19 is to be
achieved. It is essential that non-medical
personnel carry out treatment and manage
programmes because the health service
does not have sufficient resources to
cope with seriously competing health
priorities.1,3,9,12 For example, in research
projects conducted since 1996 in the
southwestern Cape, there have been
almost 200 000 treatments with mebenda-
zole that were carried out mostly by
teachers, and sometimes by EHOs, after
initial training by school nurses.12–14,20,24,32 It
was usually the schools that obtained
informed consent and teachers who
completed treatment registers. No adverse
reactions to treatment have been reported.
This scale of school-based delivery on a
regular basis would not be sustainable
by the health service working alone.
Teachers have also treated children in a
deworming project in Mpumalanga
province.18 Broad-based health partner-
ships are the only way to implement and
sustain deworming programmes in terms
of human resources and cost-effectiveness.
It is particularly important to have the
education service and community struc-
tures as active partners.9,12,40,41
Legislation and the Medicines Control
Council
The Medicines Control Council (MCC)
has a key role to play in the development
of school-based deworming because it
controls the use of registered and unregis-
tered drugs in South Africa. In contrast,
traditional medicines are not controlled
and unregistered substances are used on
a large scale. While the MCC is responsi-
ble to the public for the safety and phar-
maceutical quality of medicine, it should
be equally obliged to facilitate service
delivery of affordable essential drugs
to people living in poverty. A serious
problem is that recent amendments to
legislation concerning the scheduling,
prescription and dispensing of drugs are
blocking implementation of school-based
deworming, which has been endorsed by
the South African minister of health and
is the only effective way to reach most
children. The new legal restrictions
inadvertently violate the right of children
to receive regular anthelmintic treatment
at school. Consequently, adjustments to
the amendments are necessary as a
matter of urgency in order to allow
deworming to take place in schools under
the supervision of school nurses. With
regard to authorization for the use of
affordable unregistered medicine, Sec-
tion 21 of the Act appears to be focused
mainly on individual emergencies, such
as chemotherapy in semi-terminal cases
of cancer. Exemption from Section 36 of
the Act could permit the conditional use
of unregistered anthelmintic. It remains
to be determined whether the MCC will
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grant such an exemption. To get imported
mebendazole registered as an alternative
strategy might take as long as two years,
for various reasons.
Cost of deworming tablets, packaging,
labelling and package-inserts
In order to make deworming pro-
grammes affordable for developing
countries, international procurement
agencies have been established to cut
costs (for instance, see: www.ida.nl).
Market research has shown that single-
dose mebendazole tablets from an off-
shore source would have cost less than 25
South African cents per tablet delivered in
Cape Town in 2004, including value-
added tax and transport expenses. These
tablets are bulk-packed, often at 500 per
container. The lowest possible price
(government tender) for an equivalent
tablet registered in this country was R1.58
per tablet (single-packed) in September
2004, which is 632% of the offshore price.
Other (non-tender) South African
mebendazole tablets were quoted at
R3.10 and R6.00 per tablet in 2004, which
are respectively 1240% and 2400% of the
offshore price. Each single-packed, South
African tablet carries the cost of a card-
board box decorated with printing and
patterns in colour, a blister or foil pack
inside the box (with more printing on it),
and a package-insert. The packaging,
printing and insert combined may cost
more than the tablet. Furthermore, un-
packing a tablet to treat a child becomes a
slow process compared to accessing a
bulk supply of loose tablets, and the
discarded packing amounts to a lot of
waste for disposal. This situation is not
compatible with a quick, efficient, school-
based operation.
Outdated information about treatment of
young children and pregnant women
The package-inserts for the brands of
mebendazole that are marketed in South
Africa, contain warnings on use in preg-
nancy and for children under two years of
age. These differ from new findings
and recommendations concerning
safety.1,3,36,52–55 The incorrect warnings
confuse medical and non-medical person-
nel and have impeded, and sometimes
blocked, development and implementa-
tion of group-based deworming. New
data on safety during pregnancy (after
the first trimester) come mainly from
deworming of thousands of women with
mebendazole in Sri Lanka and Sierra
Leone, because of infestation by hook-
worm. The prevalence of these parasites
is higher in adults than in children and
they are a cause of low iron status and
anaemia, both of which can have serious
consequences for the mother and the
baby. In treated women, iron status
improved, anaemia was reduced and
there were no deleterious effects in terms
of birth outcome.1,3 It is also safe to use
praziquantel to treat schistosomiasis in
pregnant women.1,51,54,55
There is increasing evidence that
young, pre-school children need to be
dewormed and that it is safe to give them
benzimidazoles and praziquantel.1–3,36,53 In
South Africa in 2000 and 2001, studies
involving hundreds of young children
(including neonates) in Durban and at
Hlabisa in northern KZN showed that
more than 90% can be infected by worms.
These surveys also revealed that the
protozoon Giardia duodenalis, which is a
cause of diarrhoea, can be common.10,16 In
2003, the Medical Research Council of
South Africa (MRC) was commissioned
to determine the prevalence of worm
infestation in pre-school children in the
Eastern Cape (EC) and in northern KZN.30
Helminthiasis ranged from 20% in
children less than 1 year old in the EC to
46% in 5-year-olds in KZN. The preva-
lence of Giardia ranged from 9% in
children less than 1 year old to 26% in
children who were 4–5 years old. In 2004,
results of a hospital-based survey in the
EC suggested that 28–50% of epilepsy
cases might be caused by tapeworm cysts
in the brain.26 Many of the epileptics are
children.
If it becomes legally and physically
possible to implement group-based
deworming in South Africa, the aspects
outlined in the following three sections
will be of importance.
Safety of deworming
Health personnel, administrators in
education, teachers and parents are
inevitably concerned about safety and
possible adverse effects of deworming. As
specified previously, close to 200 000 doses
of mebendazole have been dispensed as
500-mg single-dose tablets during the
course of research projects in the south-
western Cape.12–14,20,24,32 Most of these treat-
ments have been by teachers or lay
persons. No reports of adverse effects
have been received. While it is clear that
children want to be treated, those who
need to treat them are confused by incor-
rect information in the package-inserts.
Quality of deworming medicine
All batches of deworming medicine
should be independently checked for
quality. This has been done in operational
research projects carried out by the MRC.
On two occasions, South African generic
mebendazole tablets did not match speci-
fications for polymorph configuration.
Pharmacological facilities are available
locally for assessing the quality of
mebendazole (and other anthelmintics)
in terms of active ingredient quality and
content, dissolution and tablet hardness.57
These tests should be a routine procedure.
Sentinel surveys in relation to public and
environmental health
It is possible that we are in a deteriorat-
ing situation with regard to infection by
helminths and protozoal pathogens,
similar to that reflected by ongoing
cholera outbreaks. The scale of migration
into urban and periurban environments
has exceeded the capacity to provide ser-
vices. Taking Khayelitsha as an example,
the population density where people live
in shacks ranges between 2250 and 33 786
per km2 (mean 15 653 per km2). Before the
influx of so many people, most of the area
was clean in terms of pollution by human
faecal material, because nobody lived
there.12 Explosive migration into unser-
viced areas could cause the rate of infec-
tion, by intestinal parasites and enteric
disease in general, to increase. Sentinel,
school-based surveys at intervals of three
to five years should be ongoing in order to
monitor parasitic infections as appropri-
ate to local conditions.4–32 This can be done
by using basic, inexpensive techniques
and would be more cost-effective and
manageable than larger-scale surveys.
Sustained checking where epidemiologi-
cal risks are high would gauge the overall
threat of enteric diseases as well as assess
the effectiveness of interventions.58,59 It is
important to note that microscopy of fae-
cal samples is not reliable for the detection
of enterobiasis23 or taeniasis (Taenia solium
is the source of cysticercosis26). When lab-
oratory diagnostic facilities are not avail-
able, simple questionnaires can yield key
information, such as the frequency of
blood in urine or faeces as an indication
of schistosomiasis,31,60 or of big worms in
faeces or vomit as confirmation of ascaria-
sis. Successful school-based deworming
can stimulate increased demand from
non-target groups, which health centres
should be ready to service.
Recommendations
1. There needs to be an effective partner-
ship between health, education and
research services, both nationally and
in all provinces, in order to optimize
delivery of school- and crêche-based
deworming. Collaboration should
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extend to the development and use of
locally relevant health education, as
well as improvement in all aspects of
sanitation and hygiene.
2. Authorization is needed for non-
medical and some paramedical per-
sonnel to carry out deworming treat-
ments with S0 and S1 anthelmintics, as
well as to obtain informed consent
and participate in management and
administration. In particular, teachers,
parents, EHOs and community health
workers should be legally entitled to
deworm children in schools, crêches,
orphanages and some other institu-
tions.
3. Albendazole and praziquantel should
be de-scheduled to S1 or S0 to enable
unimpeded use for group-based de-
worming. For the same reason, iver-
mectin and levamisole should either
be registered, or an exemption autho-
rizing procurement and use should be
issued. They could then be alternated
with benzimidazoles to reduce the
risk of development of resistance to
mebendazole and albendazole. Nita-
zoxanide is now registered in nine
South American countries as an
anthelmintic and antiprotozoal medi-
cine, and in the United States for the
treatment of giardiasis and crypto-
sporidiosis. This product might
become useful in South Africa.
4. Procurement and use of medicine
from the cheapest source, including
suppliers outside South Africa, needs
to be permitted, with monitoring
in South Africa of pharmacological
quality as a requirement.
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